Healthcare Industry News: antibiotic
News Release - August 25, 2014
NovaBay Pharmaceuticals Deploys Direct Sales Force to Market i-Lid Cleanser Across the U.S.eteran Medical Representatives Are Now Marketing NovaBay’s Innovative Eye Care Product to Ophthalmologists and Optometrists in Major Markets
i-Lid Cleanser is Formulated to Help the 40 Million Patients Who Suffer From Blepharitis and Dry Eye
EMERYVILLE, Calif.--(Healthcare Sales & Marketing Network)--NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, announced today that its i-Lid Cleanser sales force has been deployed in 10 major metropolitan areas across the United States.
“This is an exciting and important moment for NovaBay,” says Dr. Ron Najafi, Chairman and CEO of NovaBay. “For the first time, we are deploying our own team of experienced medical representatives to directly market our non-antibiotic products in a defined market with specific unmet patient needs; this has been our long standing goal at NovaBay. I welcome our medical representatives across the United States and wish them well.”
NovaBay’s newly launched sales and marketing campaign will initially target major urban areas where large numbers of individuals suffer from Dry-Eye and blepharitis. These markets include New York City, Los Angeles, Boston, Atlanta, San Francisco and other high value markets around the United States. These sales representatives recruited for this effort all have extensive experience with eye care products and medical devices—a skill set critical for rapid clinical adoption of this innovative product.
“Our sales team will provide eye care professionals with the technical and practical information that doctors need to successfully implement NovaBay’s i-Lid Cleanser in their practices,” said Glenn Moro, Vice President of Sales and Marketing. “What makes this campaign both challenging and exciting for us is that our sales team is not only selling a product, they are also attempting to bring about a paradigm shift in eyelid hygiene.”
An estimated 23 million Americans suffer from blepharitis, a condition where Staphylococci bacteria grow on eyelids, causing swelling, redness, inflammation, irritation and a crusty build-up. Another thirteen million individuals are estimated to suffer from dry eye syndrome resulting from meibomian gland dysfunction. This condition is typically a result of meibomian gland disease, where the growth of Staphylococci bacteria and the secretion of bacterial toxins cause the meibomian glands to be obstructed by thick waxy secretions. The meibomian glands are responsible for the supply of meibum, an oily substance that prevents evaporation of the eye’s tear film.
Many physicians believe that current treatments, typically antibiotics and steroids, don’t work very well for either condition—while raising concerns over antibiotic resistance and side effects. As the sales team is now explaining to doctors, i-Lid Cleanser may be able to successfully and safely treat both conditions.
“Once doctors begin trying i-Lid Cleanser, we believe they will realize that it offers a major improvement in the standard of care with the potential to become the new paradigm of eyelid care,” says Dr. Najafi.
This release contains forward-looking statements and opinions regarding the commercial potential of i-Lid Cleanser, which are based upon management's current expectations, assumptions, estimates, projections and beliefs. The words “believe,” “will,” “estimated,” “potential,” and “expectation,” are intended to identify the forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the actual effectiveness of NovaBay products and unexpected adverse side effects or inadequate therapeutic efficacy of i-Lid Cleanser, and the risk that potential customers will not perceive the benefits of i-Lid Cleanser to be the same as NovaBay believes. Other risks relating to NovaBay and its products, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay's latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading "Risk Factors." The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
Source: NovaBay Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.